ES2150294T3 - Composicion de esteres de l-dopa. - Google Patents

Composicion de esteres de l-dopa.

Info

Publication number
ES2150294T3
ES2150294T3 ES98101741T ES98101741T ES2150294T3 ES 2150294 T3 ES2150294 T3 ES 2150294T3 ES 98101741 T ES98101741 T ES 98101741T ES 98101741 T ES98101741 T ES 98101741T ES 2150294 T3 ES2150294 T3 ES 2150294T3
Authority
ES
Spain
Prior art keywords
composition
active ingredient
dopa
amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98101741T
Other languages
English (en)
Inventor
Isaac Milman
Daphne Atlas
Alexander Veinberg
Eldad Melamed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Teva Pharmaceutical Industries Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Teva Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of ES2150294T3 publication Critical patent/ES2150294T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTA INVENCION DESCRIBE UNA COMPOSICION QUE INCLUYE UN VEHICULO FARMACEUTICAMENTE ACEPTABLE Y UN PRINCIPIO ACTIVO, INCLUYENDO DICHO PRINCIPIO ACTIVO UN L - DOPA ETIL ESTER EN UNA CANTIDAD QUE ES AL MENOS UN 97 % EN PESO DE PRINCIPIO ACTIVO, Y L - DOPA EN UNA CANTIDAD QUE ES MENOR QUE UN 1 % EN PESO DE DICHO PRINCIPIO ACTIVO. ESTA INVENCION TAMBIEN DESCRIBE UN PROCEDIMIENTO PARA PREPARAR DICHA COMPOSICION. ADEMAS, ESTA INVENCION DESCRIBE UN PROCEDIMIENTO PARA TRATAR UN PACIENTE QUE PADECE LA ENFERMEDAD DE PARKINSON QUE INCLUYE ADMINISTRAR A UN PACIENTE UNA COMPOSICION FARMACEUTICA QUE INCLUYE UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE UN L - DOPA ETIL ESTER Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE.
ES98101741T 1992-12-24 1993-12-24 Composicion de esteres de l-dopa. Expired - Lifetime ES2150294T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/995,847 US5354885A (en) 1992-12-24 1992-12-24 Process for preparing ethyl ester of L-DOPA

Publications (1)

Publication Number Publication Date
ES2150294T3 true ES2150294T3 (es) 2000-11-16

Family

ID=25542272

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93120894T Expired - Lifetime ES2132170T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.
ES98101741T Expired - Lifetime ES2150294T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93120894T Expired - Lifetime ES2132170T3 (es) 1992-12-24 1993-12-24 Composicion de esteres de l-dopa.

Country Status (21)

Country Link
US (2) US5354885A (es)
EP (2) EP0610595B1 (es)
JP (1) JPH07285860A (es)
CN (1) CN1083262C (es)
AT (2) ATE178793T1 (es)
AU (1) AU684053B2 (es)
CA (1) CA2112160A1 (es)
CY (1) CY2214B1 (es)
DE (2) DE69324466T2 (es)
DK (2) DK0610595T3 (es)
ES (2) ES2132170T3 (es)
FI (1) FI107994B (es)
GR (2) GR3030073T3 (es)
HK (1) HK1012577A1 (es)
HU (1) HU218906B (es)
IL (1) IL108147A (es)
LV (1) LV12766B (es)
NO (1) NO305932B1 (es)
NZ (1) NZ250541A (es)
PT (1) PT867179E (es)
ZA (1) ZA939573B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
AU7669496A (en) * 1995-11-03 1997-05-22 University Of Kentucky Method for the intranasal administration of l-dopa prodrugs
CA2236368C (en) * 1995-11-06 2001-10-23 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU768154B2 (en) * 1996-10-13 2003-12-04 Neuroderm Ltd Treatment of Parkinson's disease
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6166081A (en) * 1997-10-09 2000-12-26 Kushnir; Moshe Methods and apparatus for treatment of Parkinson's disease
EP1063981B1 (en) 1998-03-16 2002-08-14 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
EP1135118A1 (en) * 1998-11-10 2001-09-26 Teva Pharmaceutical Industries Ltd. Dispersible compositions containing l-dopa ethyl ester
WO2000027801A1 (en) 1998-11-10 2000-05-18 Teva Pharmaceutical Industries, Ltd. Process for manufacture of l-dopa ethyl ester
RU2157196C1 (ru) * 1999-06-17 2000-10-10 Васильев Виталий Николаевич Фармацевтическая композиция в.н. васильева для восстановления функции симпатико-адреналовой системы, способ оценки индивидуальной эффективности этой композиции для терапии пациентов
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030135065A1 (en) * 2001-11-13 2003-07-17 Ramy Lidor-Hadas Process for the production of L-DOPA ethyl ester
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
HUE031167T2 (hu) 2002-03-20 2017-07-28 Civitas Therapeutics Inc A levodopa pulmonális bejuttatása
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
KR100525358B1 (ko) * 2003-08-21 2005-11-04 주식회사 이엔에프테크놀로지 카르복실 벤조트리아졸 알킬에스테르의 제조방법
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA06002344A (es) * 2003-08-29 2006-05-19 Transform Pharmaceuticals Inc Composiciones farmaceuticas y metodo para usar levodopa y carbidopa.
ATE526988T1 (de) * 2003-10-08 2011-10-15 Mallinckrodt Llc Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
RS55142B1 (sr) * 2006-02-17 2016-12-30 Ratiopharm Gmbh Deuterisani derivati kateholamina i medikamenti koji obuhvataju pomenuta jedinjenja
CN101623278B (zh) * 2008-07-09 2013-02-27 北京德众万全药物技术开发有限公司 一种含有左旋多巴和盐酸苄丝肼的药物组合物
CN107847722B (zh) 2015-05-06 2021-05-18 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
MX2018002255A (es) * 2015-08-27 2018-06-06 Prexton Therapeutics Sa Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levodopa.
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
LT4039093T (lt) 2021-02-09 2023-11-10 Biobab R&D, S.L. 3,4-dihidroksifenilalanino (dopa) enantiomerų naudojimas ir metodas, skirtas augalų patrauklumui naudingiesiems vabzdžiams didinti

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716958B (en) * 1970-10-30 1973-01-31 Hoffmann La Roche Phenylalanine amides
US3803120A (en) * 1971-09-28 1974-04-09 Hoffmann La Roche Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
US3939253A (en) * 1973-11-02 1976-02-17 Interx Research Corporation Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en) * 1975-04-17 1977-07-12 Interx Research Corporation Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4771073A (en) * 1985-12-30 1988-09-13 Merck & Co., Inc. Rectally absorbable form of L-dopa
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa
ATE76747T1 (de) * 1986-06-10 1992-06-15 Chiesi Farma Spa Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.

Also Published As

Publication number Publication date
NO934768D0 (no) 1993-12-22
EP0867179B1 (en) 2000-09-06
NZ250541A (en) 1995-12-21
CA2112160A1 (en) 1994-06-25
EP0610595A3 (en) 1994-09-21
LV12766A (lv) 2001-12-20
US5525631A (en) 1996-06-11
DK0610595T3 (da) 1999-10-25
AU5257793A (en) 1994-07-07
DE69329400T2 (de) 2001-01-18
ATE178793T1 (de) 1999-04-15
AU684053B2 (en) 1997-12-04
ES2132170T3 (es) 1999-08-16
GR3030073T3 (en) 1999-07-30
FI935847A (fi) 1994-06-25
EP0867179A1 (en) 1998-09-30
HK1012577A1 (en) 1999-08-06
HU218906B (hu) 2000-12-28
LV12766B (en) 2002-03-20
NO305932B1 (no) 1999-08-23
NO934768L (no) 1994-06-27
ATE196081T1 (de) 2000-09-15
US5354885A (en) 1994-10-11
ZA939573B (en) 1994-08-11
IL108147A (en) 1998-09-24
FI107994B (fi) 2001-11-15
CY2214B1 (en) 2002-11-08
HUT68498A (en) 1995-06-28
DE69329400D1 (de) 2000-10-12
DK0867179T3 (da) 2000-11-06
IL108147A0 (en) 1994-04-12
CN1094950A (zh) 1994-11-16
GR3034867T3 (en) 2001-02-28
PT867179E (pt) 2000-12-29
JPH07285860A (ja) 1995-10-31
EP0610595A2 (en) 1994-08-17
DE69324466T2 (de) 1999-11-25
CN1083262C (zh) 2002-04-24
DE69324466D1 (de) 1999-05-20
EP0610595B1 (en) 1999-04-14
FI935847A0 (fi) 1993-12-23
HU9303748D0 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
ES2132170T3 (es) Composicion de esteres de l-dopa.
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
IL99699A0 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
IL133585A0 (en) Soluble prodrugs of paclitaxel
HUT47217A (en) Process for producing pharmaceutical compositions containing indol derivatives as active components
CA2114014A1 (en) Advanced Drug Delivery System and Method of Treating Psychiatric, Neurological and Other Disorders with Carbamazepine
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
BG104560A (en) Long active injectable formulations containing hydrogenated castor oil
SG42446A1 (en) Pharmaceutical composition method and device for preventing or treating dry eye or disease caused therefrom
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
JPS6468320A (en) Remedy for psychotic disease or like and therapeutical solution
MY104521A (en) Treatment of depression.
BG100246A (en) N-substituted azaheterocylic carboxylic acids and their esters
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
CA2237643A1 (en) Therapeutic agent for acute hepatic failure
JPS57167922A (en) Psychotropic drug
MX9801192A (es) Nuevos peptidos opioides.
RU97105771A (ru) Способ лечения сахарного диабета

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 867179

Country of ref document: ES